Over the projection period, growth in the U.S. diabetic neuropathy market is anticipated to be driven by ongoing research and development for novel medications by key market participants. For instance, the biotechnology company Biogen declared in September 2021 that the phase 2 CONVEY study of vixotrigine had yielded topline good results. Vixotrigine, a non-opioid experimental oral pain medication for the treatment of diabetes mellitus-associated small fibre neuropathy, was evaluated for efficacy and safety in the CONVEY project, a phase 2 placebo-controlled, double-blind, enhanced enrollment, randomised withdrawal study (SFN).
Get Research Sample PDF with Market Development Insights @ https://www.coherentmarketinsights.com/insight/request-sample/5356
Impact
The financial standing of companies in all industries, including the private healthcare sector, has been harmed by the COVID-19 epidemic and lockdowns in numerous nations throughout the world.
However, because to an increase in diabetic neuropathy research and development, the COVID-19 pandemic had a favourable effect on the diabetic neuropathy market in the United States. For instance, COVID-19 patients’ diabetic neuropathy symptoms have gotten worse in 2022, according to data from U.S. Neuropathy Centers. Neuropathy can be brought on by diabetes, autoimmune conditions, cancer, and other infections. Because the immune system is weakened and patients may be more susceptible to getting infected, there is a potential rise in the demand for diabetic neuropathy medications.
Key Developments
The GBS|CIDP Foundation International launched a campaign in Pennsylvania in January 2022 to raise awareness about focal neuropathy. The purpose of this effort was to increase knowledge of and funding for focal neuropathy research. A uncommon condition known as focal neuropathy causes the immune system of the patient to target several motor neurons, leading to asymmetrical weakening in the patient’s limbs.
The U.S. diabetic neuropathy market is anticipated to grow in use of inorganic tactics such product approval by significant industry players over the forecast period. For instance, the biopharmaceutical company Lexicon Pharmaceuticals, Inc. reported in December 2020 that the U.S. Food and Drug Administration has approved the development of LX9211 for the treatment of diabetic peripheral neuropathic pain. For the treatment of diabetic peripheral neuropathic pain, LX9211 is a strong, orally administered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1).
Direct Purchase This Report with Huge Discount ( Up To 25% Off) @ https://www.coherentmarketinsights.com/insight/buy-now/5356
Key Takeaways
Due to the growing educational initiatives by the major market participants, the U.S. diabetic neuropathy market is anticipated to have a CAGR of 5.2% over the course of the projected period. For instance, in May 2022, the pharmaceutical company Averitas Pharma, Inc. held the “Speak for Your Feet” competition for New Jersey’s diabetic nerve pain sufferers, carers, and healthcare professionals (HCPs). This training programme aims to raise awareness of possible diabetic nerve pain symptoms and to establish a common language between patients and medical practitioners.
Peripheral neuropathy is thought to maintain a leading position among types in the U.S. diabetic neuropathy market as a result of the use of inorganic techniques including product approval by regulatory bodies like the U.S. Food and Drug Administration. For instance, the pharmaceutical company Pfizer, Inc. announced in July 2019 that the U.S. Food and Medicine Administration has approved the use of the drug Lyrica for the treatment of neuropathic pain brought on by diabetic peripheral neuropathy.
Averitas Pharma, Inc., Eli Lilly and Company, Tissue Tech, Inc., Johnson & Johnson Services, Inc., NeuroMetrix, Inc., Novartis AG, Ionis Pharmaceuticals, Pfizer, Inc., Alembic Pharmaceuticals Limited, GSK plc, Abbott, Glenmark Pharmaceuticals Ltd., Regenacy Pharmaceuticals, Inc., and Lupin, are significant market participants in the U.S. diabetic neuropathy market.
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Impact Analysis
- Partnership and Collaboration Scenario
- Recent Product Launches and Approvals
- Market Trends
- Regulatory Scenario
- PEST Analysis
- Reimbursement Scenario
- Cost of therapy
- Brand Mapping
- Market Dynamics
- U.S. Diabetic Neuropathy Market – Impact of Coronavirus (Covid-19) Pandemic
- Overall Impact
- Impact on Supply and Demand
- COVID-19 Impact on the market
- U.S. Diabetic Neuropathy Market, By Drug, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Tricyclic Antidepressants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Amitriptyline
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Nortyptyline
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Imipramine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Desipramine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Amitriptyline
- SSRI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Paroxetine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Citalopram
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Paroxetine
- Anticonvulsants
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Gabapentin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Pregabalin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Carbamazepine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Others (Oxcarbazepine, Topiramate and Others)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Gabapentin
- Opioids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Tramadol
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Tapentadol
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Oksikodon
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Tramadol
- SNRIs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Duloxetine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Duloxetine
- Other Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million
- Capsaicin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Lidocaine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Botilinum Toxin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Capsaicin
- Overview
- U.S. Diabetic Neuropathy Market, By Type, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Peripheral Neuropathy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Proximal Neuropathy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Autonomic Neuropathy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Focal Neuropathy
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- U.S. Diabetic Neuropathy Market, By Route of Administration, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Topical
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Injection (Intramuscular)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
- U.S. Diabetic Neuropathy Market, By Distribution Channel, 2017 – 2030, (US$ Million)
- Overview
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
- Overview
View Press Release: https://www.coherentmarketinsights.com/press-release/us-diabetic-neuropathy-market-4655
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
Email: sales@coherentmarketinsights.com
Phone: U.S.: +1-206-701-6702
U.K.: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837